isosorbide dinitrate + hydralazine

**Isosorbide dinitrate + hydralazine** is an oral fixed-dose vasodilator combination comprising the nitric-oxide-donor nitrate isosorbide dinitrate and the direct arteriolar vasodilator hydralazine hydrochloride. Marketed in the United States as **BiDil**, the 20 mg isosorbide dinitrate/37.5 mg hydralazine hydrochloride tablet is approved as an adjunct to standard therapy for heart failure in self-identified Black patients, to improve survival, prolong time to heart-failure hospitalization, and improve patient-reported functional status. Isosorbide dinitrate produces venous and arterial dilation through nitric oxide signaling, reducing preload and afterload; hydralazine predominantly dilates arterioles, reducing systemic vascular resistance and afterload, and may limit nitrate tolerance. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e1e63cd5-d1e4-4af5-bad5-1ad41ea46b00))

Brand names

BiDil

Other names

FDC I/HH-ISDNhydralazine + isosorbide dinitratehydralazine–isosorbide dinitrateisosorbide dinitrate + hydralazine hydrochlorideisosorbide dinitrate and hydralazine hydrochlorideisosorbide dinitrate/hydralazineisosorbide dinitrate/hydralazine hydrochloride